PL2521727T3 - Nowe benzoesowe pochodne pirolopirydyny i ich zastosowanie w leczeniu choroby parkinsona - Google Patents
Nowe benzoesowe pochodne pirolopirydyny i ich zastosowanie w leczeniu choroby parkinsonaInfo
- Publication number
- PL2521727T3 PL2521727T3 PL11704261T PL11704261T PL2521727T3 PL 2521727 T3 PL2521727 T3 PL 2521727T3 PL 11704261 T PL11704261 T PL 11704261T PL 11704261 T PL11704261 T PL 11704261T PL 2521727 T3 PL2521727 T3 PL 2521727T3
- Authority
- PL
- Poland
- Prior art keywords
- parkinson
- disease
- treatment
- pyrrolopyridine derivatives
- new benzoic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1050113A FR2955110A1 (fr) | 2010-01-08 | 2010-01-08 | Nouveaux derives de type pyrrolopyridine benzoique |
| EP11704261.4A EP2521727B1 (fr) | 2010-01-08 | 2011-01-07 | Nouveaux dérivés pyrrolopyridine benzoïques et leur utilisation pour le traitement de la maladie de parkinson |
| PCT/FR2011/050023 WO2011083278A1 (fr) | 2010-01-08 | 2011-01-07 | Nouveaux derives de type pyrrolopyridine benzoique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2521727T3 true PL2521727T3 (pl) | 2014-08-29 |
Family
ID=42124595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11704261T PL2521727T3 (pl) | 2010-01-08 | 2011-01-07 | Nowe benzoesowe pochodne pirolopirydyny i ich zastosowanie w leczeniu choroby parkinsona |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8546385B2 (pl) |
| EP (1) | EP2521727B1 (pl) |
| JP (1) | JP2013516448A (pl) |
| KR (1) | KR20120123042A (pl) |
| CN (1) | CN102753552A (pl) |
| AR (1) | AR079842A1 (pl) |
| AU (1) | AU2011204518A1 (pl) |
| BR (1) | BR112012016844A2 (pl) |
| CA (1) | CA2785876A1 (pl) |
| DK (1) | DK2521727T3 (pl) |
| EA (1) | EA201290601A1 (pl) |
| ES (1) | ES2478191T3 (pl) |
| FR (1) | FR2955110A1 (pl) |
| HK (1) | HK1178893A1 (pl) |
| MX (1) | MX2012007968A (pl) |
| PL (1) | PL2521727T3 (pl) |
| PT (1) | PT2521727E (pl) |
| SA (1) | SA111320080B1 (pl) |
| TW (1) | TWI473806B (pl) |
| UY (1) | UY33166A (pl) |
| WO (1) | WO2011083278A1 (pl) |
| ZA (1) | ZA201204863B (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102347368B1 (ko) | 2020-11-03 | 2022-01-07 | (주)케이메디켐 | 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998025611A1 (en) | 1996-12-13 | 1998-06-18 | Rhône-Poulenc Rorer Pharmaceuticals Inc. | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| ATE482945T1 (de) * | 1998-05-26 | 2010-10-15 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
| GB0119911D0 (en) | 2001-08-15 | 2001-10-10 | Novartis Ag | Organic Compounds |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| JP4845730B2 (ja) | 2003-07-17 | 2011-12-28 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| US8455489B2 (en) | 2003-11-10 | 2013-06-04 | Exelixis, Inc. | Substituted pyrimidine compositions and methods of use |
| FR2890072A1 (fr) * | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
| FR2903106B1 (fr) | 2006-07-03 | 2010-07-30 | Sanofi Aventis | Utilisations de 2-benzoyl-imidazopyridines en therapeutique |
| FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2903105A1 (fr) | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
| CA2674087A1 (en) | 2007-02-16 | 2008-08-21 | Memory Pharmaceuticals Corporation | 6' substituted compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
-
2010
- 2010-01-08 FR FR1050113A patent/FR2955110A1/fr not_active Withdrawn
-
2011
- 2011-01-05 SA SA111320080A patent/SA111320080B1/ar unknown
- 2011-01-06 AR ARP110100029A patent/AR079842A1/es unknown
- 2011-01-07 AU AU2011204518A patent/AU2011204518A1/en not_active Abandoned
- 2011-01-07 UY UY0001033166A patent/UY33166A/es not_active Application Discontinuation
- 2011-01-07 CA CA2785876A patent/CA2785876A1/fr not_active Abandoned
- 2011-01-07 PT PT117042614T patent/PT2521727E/pt unknown
- 2011-01-07 EP EP11704261.4A patent/EP2521727B1/fr active Active
- 2011-01-07 MX MX2012007968A patent/MX2012007968A/es not_active Application Discontinuation
- 2011-01-07 JP JP2012547533A patent/JP2013516448A/ja active Pending
- 2011-01-07 KR KR1020127017543A patent/KR20120123042A/ko not_active Application Discontinuation
- 2011-01-07 BR BR112012016844-4A patent/BR112012016844A2/pt not_active IP Right Cessation
- 2011-01-07 US US13/519,774 patent/US8546385B2/en not_active Expired - Fee Related
- 2011-01-07 EA EA201290601A patent/EA201290601A1/ru unknown
- 2011-01-07 PL PL11704261T patent/PL2521727T3/pl unknown
- 2011-01-07 DK DK11704261.4T patent/DK2521727T3/da active
- 2011-01-07 TW TW100100707A patent/TWI473806B/zh not_active IP Right Cessation
- 2011-01-07 CN CN2011800094959A patent/CN102753552A/zh active Pending
- 2011-01-07 ES ES11704261.4T patent/ES2478191T3/es active Active
- 2011-01-07 WO PCT/FR2011/050023 patent/WO2011083278A1/fr active Application Filing
-
2012
- 2012-06-29 ZA ZA2012/04863A patent/ZA201204863B/en unknown
-
2013
- 2013-05-14 HK HK13105757.7A patent/HK1178893A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201204863B (en) | 2013-09-25 |
| EP2521727B1 (fr) | 2014-03-19 |
| EA201290601A1 (ru) | 2012-12-28 |
| US20120302560A1 (en) | 2012-11-29 |
| EP2521727A1 (fr) | 2012-11-14 |
| TWI473806B (zh) | 2015-02-21 |
| WO2011083278A1 (fr) | 2011-07-14 |
| CA2785876A1 (fr) | 2011-07-14 |
| CN102753552A (zh) | 2012-10-24 |
| TW201144307A (en) | 2011-12-16 |
| MX2012007968A (es) | 2012-08-03 |
| AU2011204518A1 (en) | 2012-07-26 |
| PT2521727E (pt) | 2014-06-25 |
| JP2013516448A (ja) | 2013-05-13 |
| US8546385B2 (en) | 2013-10-01 |
| FR2955110A1 (fr) | 2011-07-15 |
| KR20120123042A (ko) | 2012-11-07 |
| HK1178893A1 (en) | 2013-09-19 |
| AR079842A1 (es) | 2012-02-22 |
| BR112012016844A2 (pt) | 2018-05-08 |
| DK2521727T3 (da) | 2014-06-16 |
| SA111320080B1 (ar) | 2014-06-23 |
| UY33166A (es) | 2011-08-31 |
| ES2478191T3 (es) | 2014-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3042910T (pt) | 2'-espiro-nucleósidos para utilização na terapia da hepatite c | |
| IL202515A (en) | Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases | |
| HK1168091A1 (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
| IL217768A (en) | Coinimod for the treatment of Crohn's disease | |
| IL221160A (en) | 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| IL221744A (en) | Use of a combination of compounds to prepare a drug to treat Parkinson's disease | |
| IL223286A0 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| IL216967B (en) | The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases | |
| HK1215787A1 (zh) | 用於治療疼痛的藥物組合 | |
| EP3628326C0 (en) | METHODS AND SUBSTANCES FOR TREATING PUMP DISEASE | |
| GB201105137D0 (en) | Therapeutic molecules for use in the suppression of Parkinson's disease | |
| IL260078B (en) | Therapy used to treat Gaucher disease | |
| HK1176936A1 (en) | Arylsulfonamide pyridine-pyridinone derivatives, preparation of same, and therapeutic use thereof | |
| GB201011411D0 (en) | Therapeutic compounds and their use | |
| HK1214771A1 (zh) | 用於治療皮膚病的製劑 | |
| PL2521727T3 (pl) | Nowe benzoesowe pochodne pirolopirydyny i ich zastosowanie w leczeniu choroby parkinsona | |
| HK1188565A1 (en) | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | |
| ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
| EP2563117A4 (en) | FORMULATIONS OF AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOESEIC DERIVATIVES FOR THE TREATMENT OF MALE PATIENTS | |
| GB201018362D0 (en) | Treatment of dupuytren's disease | |
| GB201113718D0 (en) | Treatment of Dupuytren's Disease | |
| GB201018325D0 (en) | Treatment for dupuytren's disease | |
| GB0716834D0 (en) | New formulation for treatment of skin disorders |